Results 31 to 40 of about 5,328 (181)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

JTO Clinical and Research Reports, 2022
Introduction: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion–positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer follow ...
Alexander Drilon, MD, Chao-Hua Chiu, MD, Yun Fan, MD, Byoung Chul Cho, MD, PhD, Shun Lu, MD, PhD, Myung-Ju Ahn, MD, PhD, Matthew G. Krebs, MD, PhD, Stephen V. Liu, MD, Thomas John, MD, Gregory A. Otterson, MD, Daniel S.W. Tan, MD, Tejas Patil, MD, Rafal Dziadziuszko, MD, PhD, Erminia Massarelli, MD, PhD, Takashi Seto, MD, Robert C. Doebele, MD, PhD, Bethany Pitcher, MSc, Nino Kurtsikidze, MD, Sebastian Heinzmann, PhD, Salvatore Siena, MD   +19 more
doaj   +1 more source

Entrectinib use in a platinum-refractory mucinous ovarian cancer harboring a NTRK3 gene fusion

Gynecologic Oncology Reports, 2023
Ovarian cancer is difficult to treat, and the mucinous epithelial subtype has a particularly poor response to traditional chemotherapy regimens. Entrectinib is a tumor-agnostic tyrosine kinase inhibitor with limited data regarding its use in ovarian ...
Olivia G. Beck, Melissa M. Hardesty
doaj   +1 more source

SEOM clinical guidelines for the treatment of non‑small cell lung cancer (2018) [PDF]

, 2018
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular
Carcereny, Enric, García, Y., García-Campelo, Rosario, Guirado, M., Insa, A., Juan, O., Majem, Margarita, Provencio, M., Reguart, Noemi, Trigo, J. M., Universitat Autònoma de Barcelona   +10 more
core   +4 more sources

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib

Frontiers in Oncology, 2023
Pancreatic neuroendocrine carcinoma (panNEC) is a rare disease. The rearrangements of neurotrophic tropomyosin receptor kinase (NTRK) genes are oncogenic.
Wen-Chi Wu, Wen-Chi Wu, Wen-Chi Wu, Wen-Chi Wu, Ming-Huang Chen, Ming-Huang Chen, Ming-Huang Chen   +6 more
doaj   +1 more source

MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. [PDF]

, 2019
Lung cancer remains the most lethal cancer among men and women in the United States and worldwide. The majority of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Developing new therapeutics on the basis of better understanding of
Petrek, Hannah, Yu, Ai-Ming
core   +1 more source

TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks [PDF]

, 2021
not ...
Brandi G., Rizzo A.
core   +1 more source

NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series [PDF]

, 2022
The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene fusion has represented a milestone in the era of "histology-agnostic" drugs.
Capotondi, Barbara, Carlucci, Manuela, Guerriero, Simona, Iannantuono, Giovanni Maria, Riondino, Silvia, Roselli, Mario, Rosenfeld, Roberto, Sganga, Stefano, Torino, Francesco   +8 more
core   +2 more sources

Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer

Frontiers in Oncology, 2023
IntroductionExpression of the NTRK gene is rare in solid tumors but is highly prevalent in salivary gland secretory carcinomas. Here, we report a case of a complete response to entrectinib in a patient with NTRK fusion gene-positive parotid carcinoma ...
Etsuko Moriyama, Etsuko Moriyama, Sachiko Nagasu, Sachiko Nagasu, Toshimitsu Tanaka, Toshimitsu Tanaka, Yasutaka Shimotsuura, Yasutaka Shimotsuura, Takeharu Ono, Hirohito Umeno, Jun Akiba, Akihiko Kawahara, Fumihiko Fujita, Takumi Kawaguchi, Keisuke Miwa   +14 more
doaj   +1 more source

a case report [PDF]

, 2022
personBACKGROUND: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors. ATC is frequently diagnosed at advanced stages with unresectable disease and palliative care is often indicated. Recently, several patient-tailored therapies
Cavaco, Branca Maria, Damásio, Inês, Donato, Sara, Gomes, Pedro, Horta, Mariana, Leite, Valeriano, Rito, Miguel, Simões-Pereira, Joana   +7 more
core   +1 more source

TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report

Current Oncology, 2022
NTRK gene fusions are rare oncogenic driver mutations that can be found in a broad range of neoplasms. In secretory carcinoma (SC), ETV6-NTRK3 gene fusion is seen in a majority of the cases and represents a druggable target for patients with advanced ...
Matthew S. Ernst, John T. Lysack, Martin D. Hyrcza, Shamir P. Chandarana, Desiree Hao   +4 more
doaj   +1 more source